CGI-1746 is a selective inhibitor of spleen tyrosine kinase (Syk), primarily investigated for its potential in modulating immune responses. It has been used in research to study inflammatory and autoimmune diseases due to its ability to interfere with signaling pathways in immune cells. By inhibiting Syk, CGI-1746 reduces the activation of downstream effectors involved in cytokine production, cell proliferation, and antibody-mediated responses. This makes it a valuable tool compound in studies related to rheumatoid arthritis, allergic reactions, and other conditions driven by aberrant immune activation. Its application remains largely confined to preclinical research, aiding the development of targeted therapies for immune disorders.